Canada: Canadian Competition Bureau Provides Preliminary Guidance On Pharma Patent Settlements

Settlements of patent litigation between brand name and generic pharmaceutical companies have been the subject of significant antitrust/competition enforcement activity in the United States and Europe. In Canada, the Competition Bureau (Bureau) has long expressed interest in such settlements but, until now, has not taken any enforcement action or provided guidance on its likely approach. That changed on September 23, 2014, with the release of the Bureau's White Paper Patent Litigation Settlement Agreements: A Canadian Perspective. The White Paper provides the Bureau's preliminary views as to how Canadian competition law could apply to such settlements. The White Paper makes it clear that these are preliminary views only, and that the Bureau is still considering the appropriate enforcement approach in Canada.

The White Paper does not provide clarity on the Bureau's likely enforcement approach, but does provide hints on what that approach is likely to involve. Most regrettably, the Bureau has not (yet) ruled out the possible application of the criminal conspiracy provisions of the Competition Act to such settlements. However, the Bureau has provided limited guidance on at least some of the circumstances that could attract criminal review. On the positive side, the Bureau has hinted at the types and amounts of settlement payments that would be most likely to survive antitrust scrutiny.

The highlights of the White Paper include the following:

  • As noted above, the stated goal of the paper is to provide the Bureau's preliminary views as to how Canadian competition law could apply to these settlements. The Bureau expressly states that it is still considering the appropriate enforcement approach for Canada and will engage in further public consultation.
  • The Bureau explicitly acknowledges the significant differences between U.S. and Canadian pharmaceutical regulatory regimes, including the following:
    • the lack of a notification system for patent settlements in Canada;
    • the absence in Canada of a 180-day period of exclusivity for the first generic to challenge a brand's patent;
    • "particularities" of the Canadian Patented Medicines (Notice Of Compliance) Regulations (PM (NOC) Regulations) prohibition proceedings; and
    • the potential for generics to receive damages from brands in Canada under section 8 of the PM (NOC) Regulations.
  • While it expressly acknowledges these important differences between the regulatory schemes in Canada and the United States, the Bureau takes the view that a patent litigation settlement can be anti-competitive under Canadian law and subject to Bureau review: "The Bureau does not believe that these differences diminish the role of competition analysis in reviewing potentially anti-competitive settlements."
  • Unfortunately, the Bureau has not (yet) excluded application of the criminal provisions of the Competition Act to settlements of patent litigation. Notwithstanding the 2013 decision of the U.S. Supreme Court in Actavis1 that a "rule of reason" approach is appropriate in these cases, the Bureau has said that it may review and prosecute a patent litigation settlement under the per se criminal conspiracy provision (section 45) of the Competition Act. The White Paper states that if the settlement includes conduct that goes beyond the scope of the patent, such as fixing a generic entry date beyond the term of the patent or including products that are outside of the patent litigation, the Bureau would likely review the settlement under section 45. In addition, if the Bureau finds that a patent settlement is a "naked restraint" on competition, it may pursue the matter under section 45. Unhelpfully, the White Paper does not exclude the possibility of criminal review even outside those two parameters. In other contexts, however, the Bureau has made it clear that section 45 is reserved for "hard core" criminal conduct. One hopes that future pronouncements from the Bureau will remove this uncertainty and make it clear that, absent extraordinary circumstances, patent litigation settlements will not be subject to criminal prosecution in Canada.
  • The White Paper indicates that if the Bureau examines a patent settlement under the civil provisions of the Competition Act, it is most likely to do so under section 90.1 (agreements among competitors) or section 79 (abuse of dominance). Under section 90.1, the available remedy is limited to a prohibition order going forward. Under section 79, the Competition Tribunal can make prohibition orders and may also order payment of administrative monetary penalties (AMPs) of up to $10 million. No damages or disgorgement orders are available in proceedings under section 79 or section 90.1.
  • In civil proceedings under section 79 or section 90.1, the competitive effects issue is whether the settlement is likely to result in a substantial prevention or lessening of competition (SPLC). The White Paper says that the Bureau will apply a "but for" test: i.e., but for the settlement, would the parties have been likely to compete, leading to lower-cost alternatives for consumers? The Bureau notes that the alternative "but for" the settlement is not necessarily the fully litigated outcome, but could be an alternative settlement with less restrictive terms. The Bureau provides no guidance on how it would go about determining what would have happened "but for" the settlement.
  • The White Paper distinguishes between settlements which involve only a date for generic entry, and those which also involve a payment or other consideration to the generic. The Bureau says the latter could amount to "pay for delay" agreements. The Bureau offers the generally unhelpful statement that "all else being equal, the greater the value transfer from the brand to the generic, the greater the likelihood of an SPLC." In assessing the "value transfer," the Bureau will consider not only cash payments, but also other forms of consideration: e.g., a promise by a brand name manufacturer not to introduce an authorized generic.
  • Most helpfully, the White Paper provides some guidance on the sorts and amounts of payments to a generic which could withstand scrutiny in Canada. The Bureau makes reference (with apparent approval) to the fact that, in the U.S., a payment up to the patentee's expected litigation costs can be permissible. It goes on to suggest that in Canada, in addition to litigation costs, a payment of an amount up to the patentee's estimated liability for section 8 damages under the PM (NOC) Regulations may also be defensible.
  • The White Paper ends on a controversial note with the suggestion that Canada adopt a system of mandatory notification of pharmaceutical patent settlement agreements.

Practical Guidance

While the White Paper provides only the Bureau's preliminary views, some practical tips can be gleaned from it:

  • Given the Bureau's keen interest but limited guidance, and given the Bureau's unclear position on criminal enforcement, a cautious approach is warranted pending further guidance or enforcement action by the Bureau.
  • Patent litigation settlements that could delay generic entry beyond the life of the patent are illegal in Canada and could lead to criminal prosecution under section 45 of the Competition Act.
  • Patent litigation settlements which provide for a generic entry date, without a payment or other consideration to the generic, do not appear to raise competition issues in Canada.
  • Patent litigation settlements which include a payment to the generic will be less susceptible to review if the payment does not exceed the sum of the patentee's anticipated litigation costs and its estimated section 8 damages.

To view the original article please click here.


1 Federal Trade Commission v. Actavis, 133 S. Ct. 2223 (2013).

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.